BMND15
MCID: BNM029
MIFTS: 48

Bone Mineral Density Quantitative Trait Locus 15 (BMND15)

Categories: Bone diseases, Fetal diseases, Genetic diseases, Rare diseases

Aliases & Classifications for Bone Mineral Density Quantitative Trait Locus 15

MalaCards integrated aliases for Bone Mineral Density Quantitative Trait Locus 15:

Name: Bone Mineral Density Quantitative Trait Locus 15 56 6 39
Osteoporosis 56 71
Metaphyseal Fracture, Susceptibility to 56
Compression Fracture, Susceptibility to 56
Osteoporosis, Susceptibility to 56
Fractures, Compression 71
Metaphyseal Fracture 56
Compression Fracture 56
Bmnd15 56

Characteristics:

OMIM:

56
Inheritance:
autosomal recessive
autosomal dominant


HPO:

31
bone mineral density quantitative trait locus 15:
Inheritance autosomal dominant inheritance autosomal recessive inheritance


Classifications:



External Ids:

OMIM 56 613418
MedGen 41 C3150680
SNOMED-CT via HPO 68 258211005 263681008 64859006
UMLS 71 C0029456 C0521169

Summaries for Bone Mineral Density Quantitative Trait Locus 15

MalaCards based summary : Bone Mineral Density Quantitative Trait Locus 15, also known as osteoporosis, is related to osteoporosis and osteoporosis, juvenile, and has symptoms including tremor, angina pectoris and back pain. An important gene associated with Bone Mineral Density Quantitative Trait Locus 15 is MIR2861 (MicroRNA 2861). The drugs Linagliptin and Dinoprostone have been mentioned in the context of this disorder. Affiliated tissues include bone, breast and prostate, and related phenotype is osteoporosis.

More information from OMIM: 613418

Related Diseases for Bone Mineral Density Quantitative Trait Locus 15

Diseases in the Bone Mineral Density Quantitative Trait Locus 15 family:

Bone Mineral Density Quantitative Trait Locus 4 Bone Mineral Density Quantitative Trait Locus 18
Bone Mineral Density Quantitative Trait Locus 1 Bone Mineral Density Quantitative Trait Locus 2
Bone Mineral Density Quantitative Trait Locus 3 Bone Mineral Density Quantitative Trait Locus 5
Bone Mineral Density Quantitative Trait Locus 6 Bone Mineral Density Quantitative Trait Locus 7
Bone Mineral Density Quantitative Trait Locus 8 Bone Mineral Density Quantitative Trait Locus 9
Bone Mineral Density Quantitative Trait Locus 10 Bone Mineral Density Quantitative Trait Locus 11
Bone Mineral Density Quantitative Trait Locus 12 Bone Mineral Density Quantitative Trait Locus 13
Bone Mineral Density Quantitative Trait Locus 14 Bone Mineral Density Quantitative Trait Locus 16
Bone Mineral Density Quantitative Trait Locus 17

Diseases related to Bone Mineral Density Quantitative Trait Locus 15 via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1085)
# Related Disease Score Top Affiliating Genes
1 osteoporosis 33.1 PDLIM4 MIR2861 CALCR
2 osteoporosis, juvenile 12.9
3 osteoporosis-pseudoglioma syndrome 12.8
4 nephrolithiasis/osteoporosis, hypophosphatemic, 1 12.6
5 glucocorticoid-induced osteoporosis 12.6
6 juvenile primary osteoporosis 12.6
7 nephrolithiasis/osteoporosis, hypophosphatemic, 2 12.5
8 osteoporosis and oculocutaneous hypopigmentation syndrome 12.5
9 macroepiphyseal dysplasia with osteoporosis, wrinkled skin, and aged appearance 12.3
10 hajdu-cheney syndrome 12.2
11 growth failure, microcephaly, mental retardation, cataracts, large joint contractures, osteoporosis, cortical dysplasia, and cerebellar atrophy 12.2
12 dominant hypophosphatemia with nephrolithiasis or osteoporosis 12.2
13 bone mineral density quantitative trait locus 8 12.2
14 amino aciduria with mental deficiency, dwarfism, muscular dystrophy, osteoporosis, and acidosis 12.2
15 cutis laxa osteoporosis 12.1
16 osteoporosis-macrocephaly-blindness-joint hyperlaxity syndrome 12.1
17 lrp5-related primary osteoporosis 12.1
18 bone mineral density quantitative trait locus 18 12.0
19 bone mineral density quantitative trait locus 16 11.8
20 premature ovarian failure 1 11.7
21 werner syndrome 11.6
22 aromatase deficiency 11.6
23 bone mineral density quantitative trait locus 12 11.6
24 bone disease 11.6
25 rickets 11.6
26 syndromic x-linked intellectual disability snyder type 11.6
27 lysinuric protein intolerance 11.5
28 mental retardation, x-linked, syndromic, snyder-robinson type 11.5
29 geroderma osteodysplasticum 11.5
30 hyperparathyroidism 11.5
31 premature aging syndrome, okamoto type 11.5
32 cerebrotendinous xanthomatosis 11.4
33 acth-secreting pituitary adenoma 11.4
34 cholangitis, primary sclerosing 11.4
35 spondyloocular syndrome 11.4
36 cleidocranial dysplasia 11.4
37 anorexia nervosa 11.4
38 celiac disease 1 11.4
39 systemic mastocytosis 11.4
40 spondyloepimetaphyseal dysplasia, shohat type 11.3
41 eating disorder 11.3
42 osteopetrosis 11.3
43 hypogonadotropic hypogonadism 11.3
44 multicentric osteolysis, nodulosis, and arthropathy 11.3
45 graves' disease 11.3
46 turner syndrome 11.3
47 severe congenital neutropenia 11.3
48 pituitary adenoma 4, acth-secreting 11.3
49 homocystinuria 11.3
50 calvarial doughnut lesions with bone fragility 11.3

Graphical network of the top 20 diseases related to Bone Mineral Density Quantitative Trait Locus 15:



Diseases related to Bone Mineral Density Quantitative Trait Locus 15

Symptoms & Phenotypes for Bone Mineral Density Quantitative Trait Locus 15

Human phenotypes related to Bone Mineral Density Quantitative Trait Locus 15:

31
# Description HPO Frequency HPO Source Accession
1 osteoporosis 31 HP:0000939

Symptoms via clinical synopsis from OMIM:

56
Skeletal:
osteoporosis
compression fractures (in homozygotes)
metaphyseal fractures (in homozygotes)

Clinical features from OMIM:

613418

UMLS symptoms related to Bone Mineral Density Quantitative Trait Locus 15:


tremor, angina pectoris, back pain, sciatica, equilibration disorder, muscle cramp, pelvic pain

Drugs & Therapeutics for Bone Mineral Density Quantitative Trait Locus 15

Drugs for Bone Mineral Density Quantitative Trait Locus 15 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 642)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Linagliptin Approved Phase 4 668270-12-0 10096344
2
Dinoprostone Approved Phase 4 363-24-6 5280360
3
Acetaminophen Approved Phase 4 103-90-2 1983
4
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
5
Oxycodone Approved, Illicit, Investigational Phase 4 76-42-6 5284603
6
Teriparatide Approved, Investigational Phase 4 52232-67-4 16133850
7
Risedronate Approved, Investigational Phase 4 105462-24-6 5245
8
Esomeprazole Approved, Investigational Phase 4 161796-78-7, 161973-10-0, 119141-88-7 9568614 4594
9
Tibolone Approved, Investigational Phase 4 5630-53-5
10
Medroxyprogesterone acetate Approved, Investigational Phase 4 71-58-9
11
Atorvastatin Approved Phase 4 134523-00-5 60823
12
Etanercept Approved, Investigational Phase 4 185243-69-0
13
Pamidronate Approved Phase 4 40391-99-9 4674
14
Montelukast Approved Phase 4 158966-92-8 5281040
15
Adalimumab Approved Phase 4 331731-18-1 16219006
16
Norethindrone Approved Phase 4 68-22-4 6230
17
Potassium citrate Approved, Investigational, Vet_approved Phase 4
18
Cinacalcet Approved Phase 4 226256-56-0 156419
19
Fluticasone Approved, Experimental Phase 4 90566-53-3 62924
20
Valsartan Approved, Investigational Phase 4 137862-53-4 60846
21
Angiotensin II Approved, Investigational Phase 4 68521-88-0, 4474-91-3, 11128-99-7 172198
22
Omeprazole Approved, Investigational, Vet_approved Phase 4 73590-58-6 4594
23
Olanzapine Approved, Investigational Phase 4 132539-06-1 4585
24
Dopamine Approved Phase 4 51-61-6, 62-31-7 681
25
Aripiprazole Approved, Investigational Phase 4 129722-12-9 60795
26
Vildagliptin Approved, Investigational Phase 4 274901-16-5 6918537
27
Gliclazide Approved Phase 4 21187-98-4 3475
28
Hydromorphone Approved, Illicit Phase 4 466-99-9 5284570
29
Basiliximab Approved, Investigational Phase 4 179045-86-4, 152923-56-3
30
Lamivudine Approved, Investigational Phase 4 134678-17-4 60825
31
Ribavirin Approved Phase 4 36791-04-5 37542
32
Peginterferon alfa-2a Approved, Investigational Phase 4 198153-51-4 5360545
33
Ritonavir Approved, Investigational Phase 4 155213-67-5 392622
34
Liraglutide Approved Phase 4 204656-20-2 44147092
35
Azathioprine Approved Phase 4 446-86-6 2265
36
Darunavir Approved Phase 4 635728-49-3, 206361-99-1 213039
37
Perindopril Approved Phase 4 107133-36-8, 82834-16-0 107807
38
Hydrochlorothiazide Approved, Vet_approved Phase 4 58-93-5 3639
39
Celecoxib Approved, Investigational Phase 4 169590-42-5 2662
40
Gabapentin Approved, Investigational Phase 4 60142-96-3 3446
41
Naproxen Approved, Vet_approved Phase 4 22204-53-1 1302 156391
42
Salmon Calcitonin Approved, Investigational Phase 4 47931-85-1 16129616
43
Sodium citrate Approved, Investigational Phase 4 68-04-2
44
Anastrozole Approved, Investigational Phase 4 120511-73-1 2187
45
Betamethasone Approved, Vet_approved Phase 4 378-44-9 9782
46
Radium Ra 223 dichloride Approved, Investigational Phase 4 444811-40-9
47 Abaloparatide Approved, Investigational Phase 4 247062-33-5
48
Estradiol Approved, Investigational, Vet_approved Phase 4 50-28-2 5757
49
Polyestradiol phosphate Approved Phase 4 28014-46-2
50
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865

Interventional clinical trials:

(show top 50) (show all 2136)
# Name Status NCT ID Phase Drugs
1 Pilot Study: Does Preventive Adjacent Level Cement Augmentation Positively Affect Reoperation Rates After Osteoporotic Vertebral Compression Fractures? Unknown status NCT02489825 Phase 4
2 Comparación de la Eficacia y Seguridad clínicas de Osteofortil Respecto de Forteo Unknown status NCT01945788 Phase 4 Teriparatide (rDNA origin)
3 Evaluation of the Influence of Alendronate on Wound Healing After Dental Implants in Patients With Osteoporosis Unknown status NCT00727493 Phase 4 alendronate once weekly 70mg;placebo
4 Effect of Mechanical Loading With PTH on Cortical Bone Unknown status NCT03232476 Phase 4
5 Comparisons of the Effect of Inactive and Active Vitamin D on Serum Sclerostin/dickkopf1 Levels Unknown status NCT01765010 Phase 4 Calcitriol;Alfacalcidol;Cholecalciferol;Placebo
6 A One-year Randomized Controlled Trial Evaluating the Impact of Pioglitazone Versus Linagliptin on Bone Turnover Markers Unknown status NCT02429232 Phase 4 Pioglitazone;Linagliptin
7 Pharmacodynamics Study to Investigate the Effect of Evogliptin on Bone Metabolism in Healthy Volunteers Unknown status NCT02587975 Phase 4 Evogliptin
8 Randomized Trial Comparing Efficacy and Safety of Brand Versus Generic Alendronate for Osteoporosis Treatment Unknown status NCT02371252 Phase 4 Generic alendronate
9 A Randomized, Double-blind, Placebo-controlled Study Evaluating the Analgesic Effects of the Gastrolith, in Osteoporotic Patients Suffering From Recent Skeletal Pain Caused by Vertebral Fractures Unknown status NCT01482858 Phase 4
10 Effects of Omega-3 Fatty Acids on Bone and Frailty Unknown status NCT00634686 Phase 4
11 A Comparative Study of Short-term Functional Recovery Between Early- and Late Bisphosphonate Treatment Following Hemiarthroplasty in Patients With Osteoporotic Femoral Neck Fractures Unknown status NCT02148848 Phase 4 Risedronate
12 The Treatment of Osteoporosis Using a Combination of Teriparatide (Forteo) and Denosumab Unknown status NCT02130973 Phase 4 Standard Clinical Practice Regimen;Experimental Cyclic Regimen
13 Multi-centre Clinical Trial on Hormone Replacement Treatment in China Unknown status NCT01698164 Phase 4 estradiol plus MPA;Ximingting Tablet;estradiol plus progesterone
14 A Randomized, Double Blind, Single Simulation, Parallel Controlled, Multi-center Clinical Study of Guli Capsules in the Treatment of Knee Osteoarthritis Unknown status NCT02484508 Phase 4 Guli capsule;Kangguzengsheng capsule
15 The Effect of Zoledronic Acid to Bone Fusion and Bone Metabolism of Patients With Lumbar Degenerative Disease After Lumbar Interbody Fusion Unknown status NCT01310465 Phase 4 zoledronic acid;sodium chloride
16 Maintenance of Vitamin D Sufficiency With Oral Vitamin D Supplementation in Malaysian Women of Malay and Indian Ethnicity With Post Menopausal Osteoporosis Unknown status NCT02389179 Phase 4 Vitamin D3
17 Randomized Controlled Study Evaluating the Effect of a Biotherapy Treatment (Anti-RANKL Ligand Antibody: Denosumab) on Bone and Vascular Metabolism in Osteoporotic Chronic Kidney Disease Unknown status NCT02792413 Phase 4 Denosumab;NaCl (placebo)
18 Switch Risperidone to Aripiprazole in Early Stage of Pharmacotherapy of Schizophrenia Unknown status NCT00352339 Phase 4 Rispridoen and Aripiprazole;Risperidne;Abilify
19 Open Labeled, Propective, Multicentric Phase IV Study to Examine the Influence of Pharmacogenetic Markers on the Efficacy and Side Effects in Postmenopausal, Steroid Hormone Positive Breast Cancer Patients, Who Are Treated With Letrozol. Unknown status NCT01908556 Phase 4 Letrozole
20 Magnesium Deficiency in Cirrhotic Patients Unknown status NCT01894867 Phase 4
21 A Feasibility Study to Explore the Difference in Healing Time Between Teriparatide Treatment and Standard Care on Weber B Ankle Fractures in Older People Unknown status NCT02955056 Phase 4 Forsteo
22 Effect of Enteral Genistein Supplementation on Inflammatory Cytokines, Morbidity and Mortality in Patients With Sepsis Unknown status NCT02796794 Phase 4
23 The Effect of Vitamin D Supplementation on Calcium Excretion in Thalassemia: a Dose Response Study Unknown status NCT01323608 Phase 4 Vitamin D3;Placebo
24 Adverse Effects of Glucocorticoid Therapy on Bone in Childhood Crohn's Disease Unknown status NCT00609752 Phase 4 prednisolone
25 Can Alendronate Suppress Aortic and Coronary Artery Calcification and Improve Bone Mineral Density in Chronic Peritoneal Dialysis Patients? Unknown status NCT00299572 Phase 4 alendronate (Fosamax)
26 The Immune and Clinical Impacts of Vitamin D in Patients With Chronic Musculo-skeletal Pain Unknown status NCT01417923 Phase 4 vitamin D
27 Unipedicular vs. Bipedicular Kyphoplasty for the Treatment of Osteoporotic Vertebral Fractures Completed NCT01383616 Phase 4
28 Study of Curette Use for Obtaining Restoration of Vertebral Body Anatomy in Balloon Kyphoplasty Completed NCT00810043 Phase 4
29 An International Multicentric, Multidisciplinary Prospective and Randomized Study to Compare Minimally Invasive Reduction and Fixation Using the KyphX System and Radiopaque PMMA Cement to Medical Therapy Alone for the Treatment of Painful, Acute Osteopenic Vertebral Body Compression Fractures Completed NCT00211211 Phase 4
30 Study to Evaluate the Clinical Performance of the VBS System for the Treatment of Osteoporotic Vertebral Fractures in a Multicenter, Randomized, Controlled Setting Completed NCT01847898 Phase 4
31 Effects of Teriparatide in Postmenopausal Women With Osteoporosis Previously Treated With Alendronate or Raloxifene Completed NCT00079924 Phase 4 teriparatide;aldrenodate;raloxifene
32 Prospective Randomized Study of Balloon Kyphoplasty and Vertebroplasty in Subacute (Older Than 6 Weeks) Osteoporotic Vertebral Fractures (STIC2) Completed NCT00749086 Phase 4
33 Efficacy of Teriparatide Treatment in Patients With New Forms of Inherited Low-Turnover Osteoporosis Completed NCT01360424 Phase 4 Teriparatide
34 Differential Effects of Teriparatide and Strontium Ranelate on Bone Remodeling and Formation in Postmenopausal Women With Osteoporosis Completed NCT00239629 Phase 4 Teriparatide;Strontium ranelate
35 Teriparatide Compared With Alendronate on Spine Bone Mineral Density in Postmenopausal Women With Osteoporosis Completed NCT02416271 Phase 4 Teriparatide;Alendronate;Placebo-Oral;Placebo-SC
36 Acute Effect of Teriparatide With Bisphosphonate or Denosumab on Bone Resorption Completed NCT01750086 Phase 4 Teriparatide 40-mcg subcutaneous injection;Denosumab Injection;Alendronate Oral Tablet
37 Denosumab in Current Users of Bisphosphonates for Glucocorticoid-induced Osteoporosis: a Randomized Controlled Trial Completed NCT01465568 Phase 4 Denosumab;bisphosphonates
38 Comparison of Raloxifene and Strontium Ranelate on Compliance and Efficacy in Women With Postmenopausal Osteoporosis Completed NCT01544894 Phase 4 Raloxifene;Strontium ranelate
39 A Multicenter, Prospective, Randomized, 2-Way Crossover, Open-Label Phase IV Study in Postmenopausal Women With Osteoporosis Examining Subject Satisfaction and Compliance When Actonel(Rosedronate) is Administered 35mg Once a Week or 5mg Completed NCT00549965 Phase 4 Risedronate Sodium
40 Bone Marker Changes In One Month Treatment With TERIPARATIDE (LY333334) Injections (rDNA Origin) in Men and Postmenopausal Women With Severe Osteoporosis Completed NCT00532545 Phase 4 Teriparatide
41 A One Year, Parallel, Placebo-controlled, Double-blind, Randomized Study to Assess the Effect of Monthly 150mg Oral Ibandronate Dosing Versus Placebo on Bone Quality and Strength at the Proximal Femur in Women With Osteoporosis Completed NCT02948881 Phase 4 ibandronate
42 A Study of Carotid Artery Intima-Media Thickness Following Exposure to Raloxifene HCl or Placebo Completed NCT00532246 Phase 4 raloxifene;Placebo
43 EVA: Evista Alendronate Comparison Completed NCT00035971 Phase 4 raloxifene HCI and alendronate Na
44 Short-Term Menatetrenone Therapy Increases Gamma-Carboxylation Of Osteocalcin With A Moderate Increase Of Bone Turnover In Postmenopausal Osteoporosis: A Randomized Prospective Study Completed NCT00548509 Phase 4 Menatetrenone (Vitamin K2)
45 An Open-label, Clinical Observation Extension Study to Assess Continuing Safety and Adherence in Patients With Postmenopausal Osteoporosis Receiving Monthly Oral Bonviva Completed NCT00545090 Phase 4 ibandronate [Bonviva/Boniva]
46 Open Label, Multi-centre, Longitudinal, Prospective, Phase IV Clinical Trial to Compare Two Image Technologies (ImaTx and DXA) Assessing the Anabolic Effects of PTH(1-84) in Postmenopausal Women With Primary Osteoporosis Completed NCT00583518 Phase 4 Parathyroid hormone (PTH)
47 A Prospective, Open-Label, Multi-Center, Two-Part Study to Investigate Patient Satisfaction With Monthly Dosed Ibandronate Therapy in Women With Post-Menopausal Osteoporosis or Osteopenia Transitioned From Once-Weekly Alendronate or Risendronate Completed NCT02604836 Phase 4 Ibandronate
48 A Prospective Open-Label, Multicenter Study to Evaluate the Change in Bone Turnover Markers After Once Monthly Oral Ibandronate Therapy in Treatment Naive Postmenopausal Osteoporosis Patients Completed NCT02598934 Phase 4 Ibandronate
49 A Randomized, Open-Label, Muti-Center Study to Investigate Patient Preference on Dosing in Women With Postmenopausal Osteoporosis Treated With Once-Monthly Ibandronate and Once-Weekly Alendronate. A Six Month, Two-Sequence, and Two-Period Crossover Study Completed NCT02598440 Phase 4 Alendronate;Ibandronate
50 An Open-label, Multi-centre, Randomized Study to Investigate Patient Preference on Dosing in the Once-monthly Ibandronate and the Once-weekly Risedronate in Korean Women With Postmenopausal Osteoporosis. A Six-month, Two-sequence, and Two Period Crossover Study Completed NCT00405392 Phase 4 Ibandronate (SB743830HD)

Search NIH Clinical Center for Bone Mineral Density Quantitative Trait Locus 15

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Cholecalciferol
Fluorides
Medium chain triglycerides
MEDRONATE DISODIUM
SODIUM FLUORIDE PWDR

Genetic Tests for Bone Mineral Density Quantitative Trait Locus 15

Anatomical Context for Bone Mineral Density Quantitative Trait Locus 15

MalaCards organs/tissues related to Bone Mineral Density Quantitative Trait Locus 15:

40
Bone, Breast, Prostate, Testes, Kidney, Bone Marrow, Liver

Publications for Bone Mineral Density Quantitative Trait Locus 15

Articles related to Bone Mineral Density Quantitative Trait Locus 15:

(show top 50) (show all 30004)
# Title Authors PMID Year
1
A novel microRNA targeting HDAC5 regulates osteoblast differentiation in mice and contributes to primary osteoporosis in humans. 61 56 6
19920351 2009
2
Association of genetic variation of the RIL gene, encoding a PDZ-LIM domain protein and localized in 5q31.1, with low bone mineral density in adult Japanese women. 6
12908099 2003
3
Calcitonin receptor polymorphism is associated with a decreased fracture risk in post-menopausal women. 6
9817931 1998
4
Allelic variants of human calcitonin receptor: distribution and association with bone mass in postmenopausal Italian women. 6
9571205 1998
5
Allelic variants of human calcitonin receptor in the Japanese population. 6
9003491 1997
6
Global and site-specific analysis of bone in a rat model of spinal cord injury-induced osteoporosis. 61
31886322 2020
7
Unique anabolic action of stem cell gene therapy overexpressing PDGFB-DSS6 fusion protein in OVX osteoporosis mouse model. 61
31886323 2020
8
Ferutinin directs dental pulp-derived stem cells towards the osteogenic lineage by epigenetically regulating canonical Wnt signaling. 61
30412793 2020
9
Which Drug Next? Sequential Therapy for Osteoporosis. 61
31922566 2020
10
Effect of TNF inhibitors on bone mineral density in rheumatoid arthritis patients receiving bisphosphonate: a retrospective cohort study. 61
31414225 2020
11
Osteoporosis genome-wide association study variant c.3781 C>A is regulated by a novel anti-osteogenic factor miR-345-5p. 61
31883164 2020
12
Vinpocetine inhibits RANKL-induced osteoclastogenesis and attenuates ovariectomy-induced bone loss. 61
31846839 2020
13
Low muscle mass is associated with osteoporosis: A nationwide population-based study. 61
32005424 2020
14
Abnormal microarchitecture and stiffness in postmenopausal women with isolated osteoporosis at the 1/3 radius. 61
31870633 2020
15
Patient Perceptions and Preferences for Osteoporosis Treatment. 61
30910239 2020
16
Denosumab failure associated with escape from suppression of bone resorption. 61
31733421 2020
17
Age at attainment of peak bone mineral density and its associated factors: The National Health and Nutrition Examination Survey 2005-2014. 61
31760214 2020
18
Ellagic acid protects ovariectomy-induced bone loss in mice by inhibiting osteoclast differentiation and bone resorption. 61
32026468 2020
19
Recognition of primary hyperparathyroidism: Delayed time course from hypercalcemia to surgery. 61
31561989 2020
20
Evaluation of long-term dental implant success and marginal bone loss in postmenopausal women. 61
32031087 2020
21
Lipidomic architecture shared by subclinical markers of osteoporosis and atherosclerosis: The Cardiovascular Risk in Young Finns Study. 61
31759205 2020
22
Untreated adult GH deficiency is not associated with the development of metabolic risk factors: a long-term observational study. 61
31440920 2020
23
Testing a theoretical model of imminent fracture risk in elderly women: an observational cohort analysis of the Canadian Multicentre Osteoporosis Study. 61
32034452 2020
24
Chronic administration of Cl-amidine, a pan-peptidylarginine deiminase inhibitor, does not reverse bone loss in two different murine models of osteoporosis. 61
31633211 2020
25
Simultaneous determination of illegal drug substances in dietary supplements for gout and osteoporosis using ultra-performance liquid chromatography and liquid chromatography-quadrupole-time-of-flight mass spectrometry. 61
31816474 2020
26
The effect of bisphosphosphonates on bone turnover and bone balance in postmenopausal women with osteoporosis: The T-score bone marker approach in the TRIO study. 61
31740343 2020
27
Incidence, risk factors and evaluation of osteoporosis in patients with inflammatory bowel disease - a Danish population-based inception cohort with 10 years of follow-up. 61
32016388 2020
28
Risk of Cataract Surgery and Age-Related Macular Degeneration After Initiation of Denosumab vs Zoledronic Acid for Osteoporosis: A Multi-Database Cohort Study. 61
32026309 2020
29
Comment on "Resolution without surgery of an advanced stage of medication-related osteonecrosis of the jaw (MRONJ) in a patient who could not suspend her treatment for osteoporosis", by Sarmiento (2019). 61
31277903 2020
30
Felodipine blocks osteoclast differentiation and ameliorates estrogen-dependent bone loss in mice by modulating p38 signaling pathway. 61
31877305 2020
31
PSMC6 promotes osteoblast apoptosis through inhibiting PI3K/AKT signaling pathway activation in ovariectomy-induced osteoporosis mouse model. 61
32017075 2020
32
Applying the information-motivation-behavioral model to explore the influencing factors of self-management behavior among osteoporosis patients. 61
32028930 2020
33
Computer-aided diagnosis system for osteoporosis based on quantitative evaluation of mandibular lower border porosity using panoramic radiographs. 61
32023091 2020
34
Reduction of fibrillar strain-rate sensitivity in steroid-induced osteoporosis linked to changes in mineralized fibrillar nanostructure. 61
31726107 2020
35
MicroRNA levels in bone and blood change during bisphosphonate and teriparatide therapy in an animal model of postmenopausal osteoporosis. 61
31683019 2020
36
Teriparatide may accelerate the growth of a pre-existing malignant tumor in an elderly patient with osteoporosis: A case report. 61
31929885 2020
37
Cost-effectiveness of five versus ten years of alendronate treatment prior to drug holiday for women with osteoporosis. 61
32020265 2020
38
MicroRNA-218-5p relieves postmenopausal osteoporosis through promoting the osteoblast differentiation of bone marrow mesenchymal stem cells. 61
31478244 2020
39
Effects of irisin on osteoblast apoptosis and osteoporosis in postmenopausal osteoporosis rats through upregulating Nrf2 and inhibiting NLRP3 inflammasome. 61
32010273 2020
40
Abnormal expression of miR-135b-5p in bone tissue of patients with osteoporosis and its role and mechanism in osteoporosis progression. 61
32010267 2020
41
Knowledge gap regarding osteoporosis among medical professionals in Southern India. 61
31062414 2020
42
Comparison of different calcium supplementation methods in patients with osteoporosis. 61
32010319 2020
43
The relative contributions of menopause and aging to postmenopausal osteoporosis. 61
31709834 2020
44
Zoledronic acid is effective and safe in migratory osteoporosis. 61
31411329 2020
45
Relating mechanical properties of vertebral trabecular bones to osteoporosis. 61
31813291 2020
46
Radiomics for classification of bone mineral loss: A machine learning study. 61
32033913 2020
47
Beneficial effects of anti-RANKL antibody in depression-like phenotype, inflammatory bone markers, and bone mineral density in male susceptible mice after chronic social defeat stress. 61
31790783 2020
48
Integrated metabolomic analysis for intervention effects of Gushudan on glucocorticoid-induced osteoporostic rat plasma based on RP/HILIC-UHPLC-Q-Orbitrap HRMS. 61
31874173 2020
49
Aucubin exerts anti-osteoporotic effects by promoting osteoblast differentiation. 61
32023550 2020
50
Bone marrow adiposity is inversely associated with bone mineral density in postmenopausal females. 61
31719507 2020

Variations for Bone Mineral Density Quantitative Trait Locus 15

ClinVar genetic disease variations for Bone Mineral Density Quantitative Trait Locus 15:

6 ‎‎ ‎‎ ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 MIR2861 NR_036055.1(MIR2861):n.33C>GSNV association 106 rs794728003 9:130548229-130548229 9:127785950-127785950
2 PDLIM4 RIL, -3333T-CSNV risk factor 6348
3 CALCR NM_001742.4(CALCR):c.1340T>C (p.Leu447Pro)SNV risk factor 17636 rs1801197 7:93055753-93055753 7:93426441-93426441

Expression for Bone Mineral Density Quantitative Trait Locus 15

Search GEO for disease gene expression data for Bone Mineral Density Quantitative Trait Locus 15.

Pathways for Bone Mineral Density Quantitative Trait Locus 15

GO Terms for Bone Mineral Density Quantitative Trait Locus 15

Sources for Bone Mineral Density Quantitative Trait Locus 15

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....